NCT06307522View on ClinicalTrials.gov

MRG-001 in Patients With Alcoholic Hepatitis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

December 1, 2026

Conditions

Alcoholic HepatitisAcute Alcoholic Hepatitis

Interventions

DRUG

MRG-001

Patients will receive subcutaneous administration of MRG-001 at designated visits.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

MedRegen LLC

INDUSTRY

NCT06307522 - MRG-001 in Patients With Alcoholic Hepatitis | Biotech Hunter | Biotech Hunter